Therapeutic Treatment Options for In-Transit Metastases from Melanoma
Authors:
- Francesco RussanoFRFrancesco Russano
- Marco RastrelliMRMarco Rastrelli
- Luigi Dall’olmoLDLuigi Dall’olmo
- Paolo Del FiorePFPaolo Del Fiore
- Carlomaria GianesiniCGCarlomaria Gianesini
- Antonella VecchiatoAVAntonella Vecchiato
- Marcodomenico MazzaMMMarcodomenico Mazza
- Saveria TropeaSTSaveria Tropea
- Simone MocellinSimone Mocellin
Open Access
Abstract
In-transit metastases (ITM) in melanoma present a significant therapeutic challenge due to their advanced stage and complex clinical nature. From traditional management with surgical resection, ITM treatment has evolved with the advent of systemic therapies such as immune checkpoint inhibitors and targeted therapies, which have markedly improved survival outcomes. This study aims to review and highlight the efficacy of both systemic and locoregional treatment approaches for ITM. Methods include a comprehensive review of clinical studies examining the impact of treatments like immune checkpoint inhibitors, targeted therapies, Isolated Limb Perfusion, and electrochemotherapy. The results indicate that combining systemic therapies with locoregional treatments enhances both local disease control and overall survival rates. The introduction of modern immunotherapies has not diminished the effectiveness of locoregional therapies but rather improved patient outcomes when used in conjunction. The conclusions emphasize that a multidisciplinary approach integrating systemic and locoregional therapies offers a promising strategy for optimizing the management of ITM in melanoma patients. This integrated treatment model not only improves survival rates but also enhances the quality of life for patients, suggesting a shift in standard care practices toward more comprehensive therapeutic regimens.Keywords
Funding Information
- Italian Ministry of Health
This publication has 114 references indexed in Scilit:
- The palliative role of lasers in the treatment of melanomaArchives of Dermatological Research, 2024
- In-transit metastatic cutaneous melanoma: current management and future directionsClinical & Experimental Metastasis, 2021
- Lesional therapies for in‐transit melanomaJournal of Surgical Oncology, 2020
- Meta-analysis of completion lymph node dissection in sentinel lymph node-positive melanomaBritish Journal of Surgery, 2019
- Fatal Toxic Effects Associated With Immune Checkpoint InhibitorsJAMA Oncology, 2018
- Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysisCancer Immunology, Immunotherapy, 2016
- Treatment of in‐transit melanoma with intra‐lesional interleukin‐2: A systematic reviewJournal of Surgical Oncology, 2014
- Intra‐lesional interleukin‐2 therapy for in transit melanomaJournal of Surgical Oncology, 2014
- Final report of the french multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastasesCancer, 1990
- BCG Immunotherapy in Patients With Malignant MelanomaArchives of Surgery, 1976